New 2-Year APPLAUSE-IgAN Data for Iptacopan at WCN 2026
Share
Subscribe
The treatment landscape for IgA nephropathy (IgAN) continues to evolve at a rapid pace, and new data presented at the World Congress of Nephrology (WCN) in Yokohama, Japan, suggest a potential shift in how clinicians approach disease modification in high-risk patients.
In this episode of Kidney Compass, hosts Shikha Wadhwani, MD, MS, and Brendon Neuen, MBBS, PhD, spoke with Vlado Perkovic, MBBS, PhD, about newly presented 2-year eGFR slope data from the phase 3 APPLAUSE-IgAN trial evaluating iptacopan.
0:00:00 – Episode intro & trial topic
0:00:52 – Overview of APPLAUSE trial & headline efficacy
0:02:40 – Hard outcome composite & safety profile
0:04:21 – Positioning iptacopan in guidelines & background therapy
0:05:10 – Consistency across subgroups & need for biomarkers
0:07:37 – Acute vs chronic eGFR slope with immunologic therapies
0:11:29 – Rationale for combination immunologic therapy
0:13:01 – Magnitude of effect, residual risk & early diagnosis
https://www.hcplive.com/view/kidney-compass-new-2-year-applause-igan-data-for-iptacopan-at-wcn-2026